The Cancer Letter

Inside information on cancer research and drug development

In Brief

Zinner elected chair of American College of Surgeons board of regents

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

MICHAEL ZINNER was elected chair of the Board of Regents of the American College of Surgeons.

Zinner is a general surgeon with expertise in pancreatic-hepatobiliary diseases. Since 2016, he has been the founding chief executive officer and executive medical director of the Miami Cancer Institute–Baptist Health South Florida.

Prior to that time, he served as surgeon-in-chief and Moseley Professor of Surgery at the Brigham and Women’s Hospital and Harvard Medical School. During this time, Zinner also served as clinical director and chief of surgical services at the Dana-Farber/Brigham and Women’s Cancer Center.

A fellow of the American College of Surgeons (FACS) since 1983, Zinner has previously served as vice-chair of the ACS Board of Regents (2010-2015) and chair of the ACS Board of Governors (2008-2010).

Table of Contents

YOU MAY BE INTERESTED IN

Cancer History ProjectGuest Editorial

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.
By Katerina A. Politi and Roy S. Herbst
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account